Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

>

INCOME (LOSS) FROM OPERATIONS 57,200 42,837 (99,143) 294,137

OTHER INCOME (EXPENSE):

Interest income 9,331 8,702 32,816 25,438

Interest expense (4,561) (5,399) (19,833) (18,922)

Debt exchange expense - (48,122) - (48,122)

Write-off of deferred debt

issuance costs - - - (13,105)

Gain on extinguishment of debt - - 5,319 -

Gain on sale of investment - - 5,791 -

Other income (expense), net 2,884 (1,056) 6,631 (1,172)

7,654 (45,875) 30,724 (55,883)

INCOME (LOSS) BEFORE INCOME

TAXES 64,854 (3,038) (68,419) 238,254

INCOME TAX EXPENSE 20,672 1,871 123,285 93,438

NET INCOME (LOSS) $44,182 $(4,909) $(191,704) $144,816

BASIC INCOME (LOSS) PER COMMON

SHARE $0.66 $(0.08) $(2.88) $2.39

DILUTED INCOME (LOSS) PER

COMMON SHARE $0.56 $(0.08) $(2.88) $2.08

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 67,187 61,783 66,597 60,507

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING-

ASSUMING DILUTION 78,734 61,783 66,597 69,672

Certain reclassifications of prior year amounts have been made to conform

to the current year presentation. Amounts reported in prior periods as

amortization are included now as a component of cost of sales; amounts

previously reported as depreciation (other than depreciation related to

facilities used in the production of commercial inventory and previously

included in cost of sales) are included a
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email: